

Medical Drug Clinical Criteria

Subject: Rytelo (imetelstat)

Document #: CC-0266

Publish Date: 09/10/202410/01/2025

Status: NewRevised

Last Review Date: 08/16/202408/15/2025

Table of Contents

[Overview](#)

[Coding](#)

[References](#)

[Clinical Criteria](#)

[Document History](#)

Overview

This document addresses the use of Rytelo (imetelstat). Rytelo is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). Rytelo is administered by intravenous infusion only over a period of 2 hours.

Myelodysplastic syndromes (MDS) are conditions that can occur when the body no longer makes enough healthy, normal blood cells in the bone marrow. This leads to a low number of one or more types of blood cells. A shortage of red blood cells (anemia) is the most common finding. MDS is also known as a form of blood cancer. Several types of MDS exist, based on how many types of blood cells are affected along with other factors. About one-third of MDS patients can progress to a rapidly growing cancer of bone marrow cells called acute myeloid leukemia (AML). The World Health Organization (WHO) provides classifications for myeloid neoplasms and acute leukemias. It classifies MDS into 6 main types, primarily based on how the cells in the bone marrow look under the microscope. The goal of treatment in these patients focuses on symptom control, quality of life improvement, reduction or elimination of RBC transfusions and toxicity minimization.

Clinical Criteria

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Rytelo (imetelstat)

Requests for Rytelo (imetelstat) may be approved if the following criteria are met:

I. Individual is 18 years of age or older; **AND**

II. Individual meets one of the following (A or B or C);

II.A. Individual has a diagnosis low to intermediate risk myelodysplastic syndromes (MDS); **AND**

III.1. Documentation is provided that individual is transfusion-dependent anemia requiring four (4) or more red blood cell units over eight (8) weeks in the last sixteen (16) weeks; **AND**

2. Documentation is provided that individual is relapsed, refractory, or is ineligible for erythropoiesis-stimulating (ESA) agents;

OR

B. Individual has a diagnosis of lower risk myelodysplastic syndromes (MDS) with symptomatic anemia and no del(5q) abnormalities (NCCN 2A); **AND**

1. Individual has ring sideroblasts 15% or greater (or ring sideroblasts 5% to 14% with an SF3B1 mutation); **AND**

a. Documentation is provided that individual has serum erythropoietin greater than 500mU/mL (i.e. ineligible for ESA); **OR**

b. Documentation is provided that individual has no response or relapse after luspatercept-aamt therapy;

Formatted: Font color: Auto

Formatted: Indent: Left: 0.5", Hanging: 0.31"

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Normal, Indent: Left: 0.56", No bullets or numbering

Formatted: Font: (Default) Arial, 9 pt, Font color: Auto

Formatted: Indent: Left: 0.56"

Formatted: Font: Bold

Formatted: Indent: Left: 1", Hanging: 0.19"

Formatted: Font: Bold

Formatted: Indent: Left: 1.38", Hanging: 0.19", Numbered + Level: 4 + Numbering Style: a, b, c, ... + Start at: 1 + Alignment: Left + Aligned at: 1.75" + Indent at: 2"

Formatted: Font: Bold

OR

2. Documentation is provided that individual has ring sideroblasts less than 15% (or ring sideroblasts less than 5% with an SF3B1 mutation) and serum erythropoietin greater than 500 mU/mL with no response, intolerance, relapse, or poor probability of response to immunosuppressive therapy;

OR

3. Individual has ring sideroblasts less than 15% (or ring sideroblasts less than 5% with an SF3B1 mutation) and serum erythropoietin 500 mU/mL or less; **AND**

a. Documentation is provided that individual has no response or relapse after ESA or luspatercept-aamt therapy;

OR

C. Individual has a diagnosis lower risk myelodysplastic syndromes (MDS) with symptomatic anemia with del(5q) abnormalities (NCCN 2A); **AND**

1. Documentation is provided that individual has no response to or relapse after lenalidomide or ESA; **AND**

2. Individual has poor probability of response to immunosuppressive therapy; **OR**

IV-3. Individual has no response to intolerance, or relapse after immunosuppressive therapy;

Continuation requests for Rytelo (imetelstat) may be approved if the following criteria are met:

- I. Documentation is provided that individual demonstrates continued need for treatment and has confirmation of response to treatment as evidenced by a decrease in transfusion burden from baseline

Rytelo (imetelstat) for MDS may not be approved for the following:

- I. Individual has not responded (response defined as decrease in transfusion burden from baseline) after 24 weeks of treatment (i.e. Administration of 6 doses consecutively) at maximum dose level (i.e. 7.1 mg/kg every 4 weeks); **OR**
- II. Individual has hemoglobin higher than 12 g/dL (NCCN 2A); **OR**
- III. When the above criteria are not met and for all other indications.

~~Rytelo (imetelstat) may not be approved when the above criteria are not met and for all other indications.~~

Quantity Limits

Rytelo (imetelstat) Quantity Limits

Drug	Limit
Rytelo 47 mg, 188 mg vial	7.1 mg/kg per 4 weeks

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

HCPCS

J0870 Injection, imetelstat, 1 mg [Rytelo]

ICD-10 Diagnosis

C93.10 Chronic myelomonocytic leukemia, not having achieved remission
D46.0-D46.9 D46.9 ~~Myelodysplastic syndromes~~ ~~Refractory anemia without ring sideroblasts, so stated~~

Formatted: Font: Bold

Formatted: Normal, Indent: Left: 1", No bullets or numbering

Formatted: Indent: Left: 1", Hanging: 0.19"

Formatted: Font: Bold

Formatted: Normal, Indent: Left: 0.81", Hanging: 0.19", No bullets or numbering

Formatted: Indent: Left: 1", Hanging: 0.19"

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Indent: Left: 0.56", No bullets or numbering

Formatted: Indent: Left: 0.56"

Formatted: Font: Bold

Formatted: Indent: Left: 1", Hanging: 0.19"

Formatted: Font: Bold

Formatted: Normal, Indent: Left: 1", Hanging: 0.19", No bullets or numbering

Formatted: Indent: Left: 1", Hanging: 0.19"

Formatted: Indent: Left: 0.81", Hanging: 0.38", Don't add space between paragraphs of the same style

Formatted: Font: (Default) Arial, 9 pt, Font color: Auto

Formatted: Line spacing: single

D46.1	Refractory anemia with ring sideroblasts
D46.20	Refractory anemia with excess of blasts, unspecified
D46.21	Refractory anemia with excess of blasts 1
D46.22	Refractory anemia with excess of blasts 2
D46.A	Refractory cytopenia with multilineage dysplasia
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
D46.4	Refractory anemia, unspecified
D46.Z	Other myelodysplastic syndromes
D46.9	Myelodysplastic syndrome, unspecified

Document History

New: 08/15/2025

Document History:

- 08/15/2025 – Annual Review: Add criteria for lower risk myelodysplastic syndromes per NCCN, formatting. Administrative update to add documentation. Coding Reviewed: Consolidated codes D46.0-D46.9 into one range and updated description.
- 08/16/2024 –Select Review: Create criteria for Rytelo. Coding Reviewed: Add HCPCS C9399 and J9999 for Rytelo. Add ICD-10-CM C93.10, D46.0, D46.1, D46.20, D46.21, D46.22, D46.A, D46.B, D46.C, D46.4, D46.Z, D46.9. Add HCPCS J0870 for Rytelo effective 1/1/2025 and delete HCPCS C9399 and J9999.

References

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Updated periodically.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
4. NCCN Clinical Practice Guidelines in Oncology™. © 2025 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on June 11, 2025.
 - a. Myelodysplastic Syndromes. Version 2.2025. Revised January 17, 2025.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association